GLP-1 receptor agonists work by mimicking the action of the naturally occurring incretin hormone GLP-1, which is released from the intestine in response to food intake
More recently, tirzepatide, which targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, has received approval for treating type 2 diabetes and/or obesity
It reflects the well-documented phenomenon of initial water weight loss, which tends to be greater in men due to higher baseline glycogen stores and overall fluid retention patterns
Whether retatrutide offers advantages over currently approved agents for outcomes such as insulin resistance, dyslipidaemia, or cardiovascular risk is being studied in ongoing trials
It is estimated that 1030% of individuals with NAFLD can be complicated by NASH and approximately 20% of individuals with NASH will progress to cirrhosis, hepatocellular carcinoma and/or liver failure
Cannabics Pharmaceuticals is also the proprietor of patents that describe a method of profiling the patient microbiome and cannabinoids [157], in order to select personalised cannabinoid-based therapy for subjects diagnosed with cancer [158]